Safety and Effectiveness of SA58 Nasal Spray Against COVID-19 Infection in Medical Personnel: An Open-Label, Blank-Controlled Study - Hohhot City, Inner Mongolia Autonomous Region, China, 2022

China CDC Wkly. 2023 Mar 10;5(10):218-222. doi: 10.46234/ccdcw2023.040.

Abstract

What is already known about this topic?: The active ingredient of the SA58 Nasal Spray is a broad-spectrum neutralizing antibody with a high neutralizing capacity against different Omicron sub-variants in vitro studies.

What is added by this report?: This study demonstrated the safety and effectiveness of SA58 Nasal Spray against coronavirus disease 2019 (COVID-19) infection in medical personnel for the first time.

What are the implications for public health practice?: This study provides an effective approach for the public to reduce their risk of COVID-19 infection. The findings of this research have the potential to significantly reduce the risk of infection and limit human-to-human transmission in the event of a COVID-19 outbreak.

Keywords: Broad-Spectrum Neutralizing Antibody; COVID-19; Medical Personnel; SA58 Nasal Spray.

Grants and funding

This study was supported by Sinovac Life Sciences Co., Ltd